The purpose of this study is to examine the effect of co-administration of AZD6140 and Nordette® on the blood levels of certain female hormones.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
24
90 mg tablet taken by mouth 2 times a day for 21 days per cycle
1 tablet taken by mouth once a day for 28 days per cycle
Research Site
Miami, Florida, United States
Blood levels of ethinyl estradiol, a female hormone, following oral administration of AZD6140 and Nordette®
Time frame: At scheduled times following dosing during the first 3 weeks of menstrual cycles 1 and 2.
Blood levels of various other hormones following concomitant oral administration of AZD6140 and Nordette®
Time frame: At scheduled times following dosing during the first 3 weeks of menstrual cycles 1 and 2.
Blood levels of AZD6140 and its main metabolite after concomitant oral administration of AZD6140 and Nordette®
Time frame: At scheduled times following dosing during the first 3 weeks of Cycles 1 and 2.
Safety and tolerability of AZD6140 when co-administered with Nordette®
Time frame: Screening through completion of the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.